Fisetin Modulates Human Oral Squamous Cell Carcinoma Proliferation by Blocking PAK4 Signaling Pathways

References

• FerlayJ, ColombetM, SoerjomataramI, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.v144.830350310
   PubMed Web of Science ®Google Scholar
• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• MelloFW, MeloG, PasettoJJ, SilvaCAB, WarnakulasuriyaS, RiveroERC. The synergistic effect of tobacco and alcohol consumption on oral squamous cell carcinoma: a systematic review and meta-analysis. Clin Oral Investig. 2019;23(7):2849–2859. doi:10.1007/s00784-019-02958-1
   PubMed Web of Science ®Google Scholar
• Vucicevic BorasV, FucicA, ViragM, et al. Significance of stroma in biology of oral squamous cell carcinoma. Tumori. 2018;104(1):9–14. doi:10.5301/tj.500067328885677
   PubMed Web of Science ®Google Scholar
• JiangS, DongY. Human papillomavirus and oral squamous cell carcinoma: a review of HPV-positive oral squamous cell carcinoma and possible strategies for future. Curr Probl Cancer. 2017;41(5):323–327. doi:10.1016/j.currproblcancer.2017.02.00628416242
   PubMed Web of Science ®Google Scholar
• HubbersCU, AkgulB. HPV and cancer of the oral cavity. Virulence. 2015;6(3):244–248. doi:10.1080/21505594.2014.99957025654476
   PubMed Web of Science ®Google Scholar
• GharatSA, MominM, BhavsarC. Oral squamous cell carcinoma: current treatment strategies and nanotechnology-based approaches for prevention and therapy. Crit Rev Ther Drug Carrier Syst. 2016;33(4):363–400. doi:10.1615/CritRevTherDrugCarrierSyst.201601627227910740
   PubMed Web of Science ®Google Scholar
• SpargerEE, MurphyBG, KamalFM, et al. Investigation of immune cell markers in feline oral squamous cell carcinoma. Vet Immunol Immunopathol. 2018;202:52–62. doi:10.1016/j.vetimm.2018.06.01130078599
   PubMed Web of Science ®Google Scholar
• EswaranJ, LiDQ, ShahA, KumarR. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer–opportunities, challenges, and limitations. Clin Cancer Res. 2012;18(14):3743–3749. doi:10.1158/1078-0432.CCR-11-195222595609
   PubMed Web of Science ®Google Scholar
• LiY, ZhangH, ZhaoY, et al. A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ERalpha-positive breast cancer cells. Oncogene. 2019;38(6):808–821.30177834
   PubMed Web of Science ®Google Scholar
• PaliourasGN, NaujokasMA, ParkM. Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor. Mol Cell Biol. 2009;29(11):3018–3032. doi:10.1128/MCB.01286-0819289496
   PubMed Web of Science ®Google Scholar
• WhaleAD, DartA, HoltM, JonesGE, WellsCM. PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity. Oncogene. 2013;32(16):2114–2120. doi:10.1038/onc.2012.23322689056
   PubMed Web of Science ®Google Scholar
• WangC, LiY, ZhangH, et al. Oncogenic PAK4 regulates Smad2/3 axis involving gastric tumorigenesis. Oncogene. 2014;33(26):3473–3484. doi:10.1038/onc.2013.30023934187
   PubMed Web of Science ®Google Scholar
• ZhangHY, ZhangJ, HaoCZ, et al. LC-0882 targets PAK4 and inhibits PAK4-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells. Am J Transl Res. 2017;9(6):2736–2747.28670365
   PubMed Web of Science ®Google Scholar
• LiY, WangD, ZhangH, et al. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer. Anat Rec. 2013;296(10):1561–1567. doi:10.1002/ar.22754
   Google Scholar
• BegumA, ImotoI, KozakiK, et al. Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 in oral squamous-cell carcinoma. Cancer Sci. 2009;100(10):1908–1916. doi:10.1111/cas.2009.100.issue-1019594544
   PubMed Web of Science ®Google Scholar
• SundarrajK, RaghunathA, PerumalE. A review on the chemotherapeutic potential of fisetin: in vitro evidences. Biomed Pharmacother. 2018;97:928–940. doi:10.1016/j.biopha.2017.10.16429136771
   PubMed Web of Science ®Google Scholar
• RengarajanT, YaacobNS. The flavonoid fisetin as an anticancer agent targeting the growth signaling pathways. Eur J Pharmacol. 2016;789:8–16. doi:10.1016/j.ejphar.2016.07.00127377217
   PubMed Web of Science ®Google Scholar
• MaherP. Protective effects of fisetin and other berry flavonoids in parkinson’s disease. Food Funct. 2017;8(9):3033–3042. doi:10.1039/C7FO00809K28714503
   PubMed Web of Science ®Google Scholar
• WonDH, ChungSH, ShinJA, et al. Induction of sestrin 2 is associated with fisetin-mediated apoptosis in human head and neck cancer cell lines. J Clin Biochem Nutr. 2019;64(2):97–105. doi:10.3164/jcbn.18-6330936621
   PubMed Web of Science ®Google Scholar
• FuCY, ChenMC, TsengYS, et al. Fisetin activates hippo pathway and JNK/ERK/AP-1 signaling to inhibit proliferation and induce apoptosis of human osteosarcoma cells via ZAK overexpression. Environ Toxicol. 2019;34(8):902–911. doi:10.1002/tox.2276131044527
   PubMed Web of Science ®Google Scholar
• GuoG, ZhangW, DangM, YanM, ChenZ. Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway. J Biochem Mol Toxicol. 2019;33(4):e22268. doi:10.1002/jbt.2019.33.issue-430431692
   PubMed Web of Science ®Google Scholar
• SiY, LiuJ, ShenH, et al. Fisetin decreases TET1 activity and CCNY/CDK16 promoter 5hmC levels to inhibit the proliferation and invasion of renal cancer stem cell. J Cell Mol Med. 2019;23(2):1095–1105. doi:10.1111/jcmm.2019.23.issue-230411496
   PubMed Web of Science ®Google Scholar
• LiYS, QinXJ, DaiW. Fisetin suppresses malignant proliferation in human oral squamous cell carcinoma through inhibition of Met/Src signaling pathways. Am J Transl Res. 2017;9(12):5678–5683.29312520
   PubMed Web of Science ®Google Scholar
• ZhangJ, ZhangHY, WangJ, et al. GL-1196 suppresses the proliferation and invasion of gastric cancer cells via targeting PAK4 and inhibiting PAK4-mediated signaling pathways. Int J Mol Sci. 2016;17(4):470. doi:10.3390/ijms1704047027077843
   PubMed Web of Science ®Google Scholar
• SabarwalA, AgarwalR, SinghRP. Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells. Mol Carcinog. 2017;56(2):499–514. doi:10.1002/mc.v56.227254419
   PubMed Web of Science ®Google Scholar
• RaneC, SenapedisW, BalogluE, et al. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth. Sci Rep. 2017;7:42555. doi:10.1038/srep4255528198380
   PubMed Web of Science ®Google Scholar
• WangK, HuynhN, WangX, et al. PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines. Am J Transl Res. 2019;11(6):3353–3364.31312349
   PubMed Web of Science ®Google Scholar
• MurrayBW, GuoC, PirainoJ, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010;107(20):9446–9451. doi:10.1073/pnas.091186310720439741
   PubMed Web of Science ®Google Scholar
• ZhangJ, WangJ, GuoQ, et al. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett. 2012;317(1):24–32. doi:10.1016/j.canlet.2011.11.00722085492
   PubMed Web of Science ®Google Scholar
• GuoQ, SuN, ZhangJ, et al. PAK4 kinase-mediated SCG10 phosphorylation involved in gastric cancer metastasis. Oncogene. 2014;33(25):3277–3287. doi:10.1038/onc.2013.29623893240
   PubMed Web of Science ®Google Scholar
• ZhuangT, ZhuJ, LiZ, et al. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. Oncotarget. 2015;6(41):43853–43868. doi:10.18632/oncotarget.v6i4126554417
   PubMedGoogle Scholar
• Abu AboudO, ChenCH, SenapedisW, BalogluE, ArguetaC, WeissRH. Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth. Mol Cancer Ther. 2016;15(9):2119–2129. doi:10.1158/1535-7163.MCT-16-019727390344
   PubMed Web of Science ®Google Scholar
• LauritanoD, LuccheseA, ContaldoM, et al. Oral squamous cell carcinoma: diagnostic markers and prognostic indicators. J Biol Regul Homeost Agents. 2016;30(2 Suppl 1):169–176.27469565
   PubMed Web of Science ®Google Scholar
• RiveraC, OliveiraAK, CostaRAP, De RossiT, Paes LemeAF. Prognostic biomarkers in oral squamous cell carcinoma: a systematic review. Oral Oncol. 2017;72:38–47. doi:10.1016/j.oraloncology.2017.07.00328797460
   PubMed Web of Science ®Google Scholar
• Cuevas-NunezMC, GomesCBF, WooSB, et al. Biological significance of 5-hydroxymethylcytosine in oral epithelial dysplasia and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(1):59–73.e52. doi:10.1016/j.oooo.2017.06.00628743666
   PubMed Web of Science ®Google Scholar